Cannabis y Enfermedad Inflamatoria Intestinal: Una Exploración del Potencial Medicinal

Autores/as

DOI:

https://doi.org/10.29105/agricolis.v1i3.23

Palabras clave:

colitis, gastrointestinal, cannabinoides, endocannabinoidoma, sistema endocannabinoide

Resumen

Enfermedad inflamatoria intestinal (EII) engloba afecciones de inflamación crónica del tracto gastrointestinal. Éstas se ocurren tanto en humanos como en otros animales y su prevalencia varía globalmente. Aunque su etiología exacta permanece incierta, se acepta que resultan de una interacción compleja entre el sistema inmunológico, microbiota intestinal, susceptibilidad genética y factores ambientales. El tratamiento farmacológico convencional no asegura beneficios a largo plazo. Recientemente, se ha investigado el uso de compuestos naturales de plantas, como los cannabinoides del cannabis (Cannabis sativa L.), como potenciales agentes terapéuticos para EII. Los fitocannabinoides interactúan con la endocannabinoidoma, que desempeña un papel crucial en la salud gastrointestinal y en la modulación de los procesos patológicos como la inflamación crónica. En el presente trabajo abordaremos las características de la EII, la planta de cannabis, su potencial terapéutico y su historia de uso medicinal por la humanidad.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Barcaccia, G., Palumbo, F., Scariolo, F., Vannozzi, A., Borin, M., Bona, S., 2020. Potentials and Challenges of Genomics for Breeding Cannabis Cultivars. Front. Plant Sci. 11. https://doi.org/10.3389/fpls.2020.573299

Brierley, D.I., Samuels, J., Duncan, M., Whalley, B.J., Williams, C.M., 2016. Cannabigerol is a novel, well-tolerated appe-tite stimulant in pre-satiated rats. Psychopharmacology (Berl). 233, 3603–3613. https://doi.org/10.1007/s00213-016-4397-4

Busquets-García, A., Bolaños, J.P., Marsicano, G., 2022. Metabolic Messengers: endocannabinoids. Nat. Metab. 4, 848–855. https://doi.org/10.1038/s42255-022-00600-1

Citti, C., Linciano, P., Russo, F., Luongo, L., Iannotta, M., Maione, S., Laganà, A., Capriotti, A.L., Forni, F., Vandelli, M.A., Gigli, G., Cannazza, G., 2019. A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimi-metic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol. Sci. Rep. 9, 20335. https://doi.org/10.1038/s41598-019-56785-1

Couch, D.G., Maudslay, H., Doleman, B., Lund, J.N., O’Sullivan, S.E., 2018. The Use of Cannabinoids in Colitis: A Sys-tematic Review and Meta-Analysis. Inflamm. Bowel Dis. 24, 680–697. https://doi.org/10.1093/ibd/izy014

de Mattos, B.R.R., Garcia, M.P.G., Nogueira, J.B., Paiatto, L.N., Albuquerque, C.G., Souza, C.L., Fernandes, L.G.R., Tama-shiro, W.M.D.S.C., Simioni, P.U., 2015. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biolog-ical Treatments. Mediators Inflamm. 2015, 1–11. https://doi.org/10.1155/2015/493012

Di Marzo, V., Piscitelli, F., 2015. The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurothera-peutics 12, 692–698. https://doi.org/10.1007/s13311-015-0374-6

ElSohly, M.A., Radwan, M.M., Gul, W., Chandra, S., Galal, A., 2017. Phytochemistry of Cannabis sativa L., in: Phyto-cannabinoids: Unraveling the Complex Chemistry and Pharmacology of Cannabis Sativa. Progress in the Chemistry of Organic Natural Products, Cham, pp. 1–36. https://doi.org/10.1007/978-3-319-45541-9_1

Eltantawy, N., El-Zayyadi, I.A.E.H., Elberry, A.A., Salah, L.M., Abdelrahim, M.E.A., Kassem, A.B., 2023. A review article of inflammatory bowel disease treatment and pharmacogenomics. Beni-Suef Univ. J. Basic Appl. Sci. 12. https://doi.org/10.1186/s43088-023-00361-0

Farag, S., Kayser, O., 2017. The Cannabis Plant: Botanical Aspects, in: Press, A. (Ed.), Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment. Elsevier, London, pp. 3–12. https://doi.org/10.1016/B978-0-12-800756-3.00001-6

Fernández-Ruiz, J., Romero, J., Ramos, J.A., 2015. Endocannabinoids and Neurodegenerative Disorders: Parkinson’s Disease, Huntington’s Chorea, Alzheimer’s Disease, and Others, in: Pertwee, R.G. (Ed.), Endocannabinoids, Handbook of Experimental Pharmacology. Springer International Publishing, Cham, pp. 233–259. https://doi.org/10.1007/978-3-319-20825-1_8

Guo, B., Bian, Z., Qiu, H., Wang, Yi-tao, Wang, Ying, 2017. Biological and clinical implications of herbal medicine and natural products for the treatment of inflammatory bowel disease 37–48. https://doi.org/https://doi.org/10.1111/nyas.13414

Hartsel, J.A., Boyar, K., Pham, A., Silver, R.J., Makriyannis, A., 2019. Cannabis in Veterinary Medicine: Cannabinoid Therapies for Animals, in: Nutraceuticals in Veterinary Medicine. Springer International Publishing, Cham, pp. 121–155. https://doi.org/10.1007/978-3-030-04624-8_10

Hourfane, S., Mechqoq, H., Bekkali, A.Y., Rocha, J.M., El Aouad, N., 2023. A Comprehensive Review on Cannabis sativa Ethnobotany, Phytochemistry, Molecular Docking and Biological Activities. Plants 12, 1–43. https://doi.org/10.3390/plants12061245

Iffland, K., Grotenhermen, F., 2017. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res. 2, 139–154. https://doi.org/10.1089/can.2016.0034

Ishiguro, H., 2023. Editorial: Targeting the endocannabinoidome in neurodegenerative disorders. Front. Aging Neurosci. 14. https://doi.org/10.3389/fnagi.2022.1116635

Jergens, A.E., Simpson, K.W., 2012. Inflammatory bowel disease in veterinary medicine. Front. Biosci. - Elit. 4 E, 1404–1419. https://doi.org/10.2741/e470

Kicman, A., Toczek, M., 2020. The effects of cannabidiol, a non-intoxicating compound of cannabis, on the cardiovascu-lar system in health and disease, International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21186740

Klumpers, L.E., Thacker, D.L., 2019. A brief background on cannabis: From plant to medical indications. J. AOAC Int. 102, 412–420. https://doi.org/10.5740/jaoacint.18-0208

Lu, Q., Yang, M.F., Liang, Y.J., Xu, J., Xu, H.M., Nie, Y.Q., Wang, L.S., Yao, J., Li, D.F., 2022. Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics. J. Inflamm. Res. 15, 1825–1844. https://doi.org/10.2147/JIR.S353038

Malik, T.A., 2015. Inflammatory Bowel Disease. Historical Perspective, Epidemiology, and Risk Factors. Surg. Clin. North Am. https://doi.org/10.1016/j.suc.2015.07.006

Martínez, V., Iriondo De-Hond, A., Borrelli, F., Capasso, R., Del Castillo, M.D., Abalo, R., 2020. Cannabidiol and other non-psychoactive cannabinoids for prevention and treatment of gastrointestinal disorders: Useful nutraceuticals? Int. J. Mol. Sci. 21. https://doi.org/10.3390/ijms21093067

Naftali, T., Mechulam, R., Lev, L.B., Konikoff, F.M., 2014. Cannabis for Inflammatory Bowel Disease. Dig. Dis. 32, 468–474. https://doi.org/10.1159/000358155

Nduma, B.N., Mofor, K.A., Tatang, J., Ekhator, C., Ambe, S., Fonkem, E., 2023. The Use of Cannabinoids in the Treatment of Inflammatory Bowel Disease (IBD): A Review of the Literature. Cureus 15. https://doi.org/10.7759/cureus.36148

Ramos-Guerrero, L., Montalvo, G., Cosmi, M., García-Ruiz, C., Ortega-Ojeda, F.E., 2022. Classification of Various Mari-juana Varieties by Raman Microscopy and Chemometrics. Toxics 10, 115. https://doi.org/10.3390/toxics10030115

Russo, E.B., 2015. The Pharmacological History of Cannabis, in: Handbook of Cannabis. https://doi.org/10.1093/acprof:oso/9780199662685.003.0002

Saez, A., Herrero-Fernandez, B., Gomez-Bris, R., Sánchez-Martinez, H., Gonzalez-Granado, J.M., 2023. Pathophysiology of Inflammatory Bowel Disease: Innate Immune System. Int. J. Mol. Sci. 24. https://doi.org/10.3390/ijms24021526

Sałaga, M., Abalo, R., Fichna, J., 2017. Chapter 49. the Effects on Gastrointestinal Function : An Overview, Handbook of Cannabis and Related Pathologies. Elsevier Inc. https://doi.org/10.1016/B978-0-12-800756-3/00056-9

Seyedian, S.S., Nokhostin, F., Malamir, M.D., 2019. A review of the diagnosis, prevention, and treatment methods of in-flammatory bowel disease. J. Med. Life 12, 113–122. https://doi.org/10.25122/jml-2018-0075

Shah, S.C., Itzkowitz, S.H., 2022. Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology 162, 715-730.e3. https://doi.org/10.1053/j.gastro.2021.10.035

Toczek, M., Malinowska, B., 2018. Enhanced endocannabinoid tone as a potential target of pharmacotherapy. Life Sci. 204, 20–45. https://doi.org/10.1016/j.lfs.2018.04.054

Turner, S.E., Williams, C.M., Iversen, L., Whalley, B.J., 2017. Molecular Pharmacology of Phytocannabinoids, Spanier. ed, Progress in the chemistry of organic natural products. Progress in the Chemistry of Organic Natural Products, Cham. https://doi.org/10.1007/978-3-319-45541-9_3

Yamamoto-Furusho, J.K., Bosques-Padilla, F., de-Paula, J., Galiano, M.T., Ibañez, P., Juliao, F., Kotze, P.G., Rocha, J.L., Steinwurz, F., Veitia, G., Zaltman, C., 2017. Diagnosis and treatment of inflammatory bowel disease: First Latin Ameri-can Consensus of the Pan American Crohn’s and Colitis Organisation. Rev. Gastroenterol. México (English Ed. 82, 46–84. https://doi.org/10.1016/j.rgmxen.2016.07.003

Descargas

Publicado

2024-09-27

Cómo citar

Cárdenas Noriega , K. A. (2024) «Cannabis y Enfermedad Inflamatoria Intestinal: Una Exploración del Potencial Medicinal», Scientia Agricolis Vita, 1(3), pp. 36–52. doi: 10.29105/agricolis.v1i3.23.

Número

Sección

Artículos de revisión

Categorías